NewsTuberculosis: A Neglected Pandemic - The German Center for Research and Innovation (GCRI), in cooperation with the Max Planck Florida Institute, will host a discussion on the treatments and challenges of tuberculosis

Tuberculosis: A Neglected Pandemic - The German Center for Research and Innovation (GCRI), in cooperation with the Max Planck Florida Institute, will host a discussion on the treatments and challenges of tuberculosis

A discussion on TB research and the current state of immunobiology at the German Center for Research and Innovation (GCRI) on Thursday, March 31. Featuring Prof. Stefan H.E. Kaufmann (Max Planck Institute for Infection Biology), Dr. Carl Nathan (Weill Cornell Medical College), and Dr. Ann Ginsberg (Global Alliance for TB Drug Development).

The German Center for Research and Innovation (GCRI), in cooperation with the Max Planck Florida Institute, will host a discussion on the treatments and challenges of tuberculosis on Thursday, March 31, from 7:00 to 9:00 p.m. The event will take place at the German House New York (871 United Nations Plaza, First Avenue, btw. 48th & 49th Streets).

Tuberculosis, along with HIV/AIDS, is one of today’s deadliest threats. Killing one person every 20 seconds, 10 million new cases of active TB develop each year worldwide, of which one quarter are fatal. While treatments are available, numbers of multi-drug resistant infections are on the rise. What are the challenges researchers face in developing a cure? What advances are being made, and how will they impact the developed and developing world? Join highly cited immunologist Prof. Stefan H.E. Kaufmann (Max Planck Institute for Infection Biology) and Robert Koch Award recipient Dr. Carl Nathan (Weill Cornell Medical College) for answers to these questions and insight into the global state of immunobiology. Prof. Kaufmann, who is the founding director and director of the Department of Immunobiology of the Max Planck Institute for Infection Biology in Berlin, is also the president of the International Union of Immunological Societies (IUIS). His scientific interests include immunity to bacterial pathogens with an emphasis on tuberculosis and rational vaccine design. Dr. Nathan’s current research focuses on the biochemical basis of the Mycobacterium tuberculosis strain’s resistance to treatment. He is the R.A. Rees Pritchett Professor and chairman of the Department of Microbiology and Immunology at Weill Cornell Medical College in New York. Dr. Ann Ginsberg, Chief Medical Officer of the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit product development partnership focused on the discovery and development of improved treatments for TB and ensuring their affordability for patients around the world, will moderate.

The German Center for Research and Innovation, www.GermanInnovation.org, provides information and support for the realization of cooperative and collaborative projects between North America and Germany in the humanities, science, and technology. With the goal of enhancing communication on the critical challenges of the 21st century, the GCRI hosts a wide range of events from lectures and exhibitions to workshops and science dinners. Opened in February 2010, the GCRI was created as a cornerstone of the German government’s initiative to internationalize science and research and is one of five centers worldwide.

Source: German Center for Research and Innovation New York Editor by , Deutsches Wissenschafts- und Innovationshaus New Y Countries / organization: Germany USA Topic: Life Sciences

Promoter

About us